American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
GA
Galderma Group AG/ADR
$41.51
-0.19%
OTC: GALDY · 15-min delayed
GALDYOTC
About Galderma Group AG/ADR
GALDERMA GROUP AG U/ADR
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
OTC: GALDY
$41.51
-0.19%
15-minute delayed · data by Polygon.io
Past year
$23.12
$43.92
52-week range
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Trading 5% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Galderma Group AG/ADR.
Write a review
Newsroom
News about Galderma Group AG/ADR
DYSPORT Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - Kaken Pharma, Novartis, Glenmark Pharma, Sun Pharma, Teva Pharmaceutical, Bayer, and Galderma
Lip Augmentation Market Size to Reach USD 17.37 Billion by 2035 with 8.21% CAGR – SNS Insider
Aesthetic Medicine Market Forecast 2025-2033: A $233.67 Billion Revenue Opportunity with Key Insights by Region | Astute Analytica
L’ORÉAL RÉALISE AVEC SUCCÈS UNE ÉMISSION OBLIGATAIRE EN TROIS TRANCHES POUR UN MONTANT TOTAL DE 1,750 MILLIARDS D’EUROS
L’Oréal successfully prices a 1.750 billion euro triple tranche bond
News & sentiment via Polygon.io
Explore
Browse all →
